Dasiglucagon + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Trial Timeline
Nov 1, 2018 → Mar 11, 2019
NCT ID
NCT03688711About Dasiglucagon + Placebo
Dasiglucagon + Placebo is a phase 3 stage product being developed by Zealand Pharma for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03688711. Target conditions include Hypoglycemia, Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04836273 | Phase 2 | Completed |
| NCT04172441 | Phase 2/3 | Completed |
| NCT03735225 | Phase 1 | Completed |
| NCT03688711 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia